Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
2021
2020
2019
ASCO 2021 - Breast Cancer
ASCO 2021 Wrap-Up - Breast Cancer
ASCO 2020 - Lung Cancer
ASCO 2020 - Wrap Up
ASH 2020 - Multiple Myeloma
SABCS 2020 Highlights
ASH 2019 Post Wrap-Up
ASH 2019 Multiple Myeloma
Two Different Doses of Ixazomib Assessed in Patients with Relapsed MM Not Refractory to Bortezomib
Conference Correspondent
,
ASH
Conference Correspondent
A randomized phase 2 study evaluated the safety and antimyeloma activity of 2 different doses of ixazomib (4 mg or 5.5 mg weekly for 3 weeks with a week off) plus dexamethasone (40 mg weekly) in patients with relapsed multiple myeloma (MM) but who were not refractory to bortezomib; results of this study were reported at the meeting.
Read More ›
Durable Benefit with Addition of Elotuzumab to Lenalidomide/Dexamethasone in Patients with RRMM
Conference Correspondent
,
ASH
Conference Correspondent
Researchers presented updated results of the randomized phase 3 ELOQUENT-2 study that evaluated the anti-SLAM7 monoclonal antibody elotuzumab plus lenalidomide/dexamethasone versus lenalidomide/dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM).
Read More ›
Management of Infusion-Related Reactions Associated with Daratumumab Monotherapy in RRMM
Conference Correspondent
,
ASH
Conference Correspondent
Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study.
Read More ›
Patient Preferences on Treatment Attributes in MM
Conference Correspondent
,
ASH
Conference Correspondent
Researchers reported results of an online survey that examined the preferences of patients with multiple myeloma (MM) on route of administration and individual treatment-related adverse events.
Read More ›
ISS Staging May Be Inadequate in Classifying All Patients with Newly Diagnosed MM by Disease and Symptom Burden
Conference Correspondent
,
ASH
Conference Correspondent
This study analyzed data from the longitudinal CoMMpass trial led by the Multiple Myeloma Research Foundation to determine the degree to which the International Staging System (ISS) stage was associated with disease and symptom burden in patients with newly diagnosed multiple myeloma (MM).
Read More ›
Bortezomib-Based Induction and Maintenance Therapy Results in Durable Survival Improvements in Newly Diagnosed MM Patients
Conference Correspondent
,
ASH
Conference Correspondent
Researchers reported long-term follow-up results of the HOVON-65/GMMG-HD4 trial that evaluated survival outcomes with bortezomib-based induction and maintenance regimens followed by high-dose melphalan and autologous stem-cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma (MM) compared with the standard regimen. The impact of the bortezomib-based regimen on survival in the high-risk cytogenetic and renally impaired subset of patients was also reported.
Read More ›
Clinical Benefit of Bortezomib/Melphalan/Prednisone Followed by Lenalidomide/Dexamethasone in Elderly Newly Diagnosed Patients with MM
Conference Correspondent
,
ASH
Conference Correspondent
To further optimize therapy, this study identified subgroups that benefited least from bortezomib/melphalan/prednisone followed by lenalidomide/dexamethasone regimen in newly diagnosed patients aged 65 to 80 years with multiple myeloma (MM) included in the GEM2010 trial.
Read More ›
Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study
Conference Correspondent
,
ASH
Conference Correspondent
Daratumumab in combination with pomalidomide and dexamethasone is being evaluated in a 4-arm, multicenter, phase 1b study in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma. Initial findings show deep and durable responses, a high response rate, and good tolerability.
Read More ›
Carfilzomib plus Filanesib versus Carfilzomib in Patients with Advanced Multiple Myeloma
Conference Correspondent
,
ASH
Conference Correspondent
Filanesib, a kinesin spindle protein inhibitor, has demonstrated promising clinical activity in patients with multiple myeloma refractory to proteasome inhibitors and immunomodulatory drugs. This new combination demonstrated good tolerability and an increased observed response rate compared with carfilzomib alone.
Read More ›
Clinical Impact of MRD Monitoring in Elderly Patients with MM
Conference Correspondent
,
ASH
Conference Correspondent
The elderly are an important subgroup within multiple myeloma patients, and it is important to continuously monitor MRD to help balance efficacy and toxicity of treatments. Researchers demonstrated that MRD negativity was associated with significant improved survival regardless of age or cytogenetic risk.
Read More ›
Page 29 of 31
22
23
24
25
26
27
28
29
30
31
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION